



Nova Eye Medical Introduces Bespoke Forceps to Streamline the Canaloplasty Procedure

Fremont, California, 25 March 2021 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce the introduction of the Reiss Patel Technique or RPT “All-In-One” Forceps, for use with the Company’s proprietary iTrack™ canaloplasty microcatheter.

Designed in collaboration with experienced canaloplasty surgeons Dr. George Reiss and Dr. Shamil Patel of Eye Physicians & Surgeons of Arizona, the RPT “All-In-One” Forceps incorporate a number of features designed to streamline the use of the iTrack™ canaloplasty microcatheter during the ab-interno canaloplasty procedure.

First introduced in 2008, the iTrack™ canaloplasty microcatheter is considered by many surgeons to be the gold-standard in canaloplasty and is supported by a growing body of clinical evidence attesting to its efficacy and safety profile. At just 250 microns in diameter and with a flexible design to permit catheterization of the full 360 degrees of the canal, however, Dr. Patel observed that some of his peers found the iTrack™ ab-interno canaloplasty procedure technically challenging to perform.

The RPT “All-In-One” Forceps were thus designed to combine the surgical steps of goniotomy creation and canal intubation in order to both simplify and streamline the ab-interno canaloplasty procedure.

“During the procedure, the surgeon manually intubates Schlemm’s canal with the iTrack™ microcatheter. With the RPT “All-In-One” Forceps we can simplify this surgical step and reduce surgical duration,” commented Dr. Patel.

“Importantly, by enabling the surgeon to intubate the canal with the iTrack™ microcatheter immediately following the creation of the goniotomy we can reduce the risk of heme obscuring the view of the otomy site.”



“With any ophthalmic surgery we want to limit the amount of time that we are in the eye. When using the RPT “All-In-One” Forceps we don’t need to exit the eye between the creation of the goniotomy and intubation of the canal. This significantly reduces surgical time,” added Dr. Patel.

The RPT “All-In-One” Forceps feature a unique square cleat design, which provides a firm grasp of the microcatheter as it is threaded into the canal. Importantly, this design also reduces the risk of crimping or crushing the microcatheter, which can damage its inner workings.

“The iTrack™ canaloplasty microcatheter offers significant utility to my POAG patients. I am hopeful that the greater surgical efficiency afforded by the RPT “All-In-One” Forceps will improve the adoption and application rate of the iTrack™ procedure in the treatment of mild-moderate glaucoma patients,” concluded Dr. Patel.

The RPT “All-In-One” Forceps are available for use in the USA. To confirm availability in regions outside of the USA, please contact your local Nova Eye Medical representative or contact Nova Eye Medical directly at info@nova-eye.com.

ABOUT AB-INTERNO CANALOPLASTY

Canaloplasty was first introduced in 2005 as an alternative to trabeculectomy in the treatment of severe glaucoma, performed via an ab-externo approach. Over time, refinement of the procedure by physicians has seen canaloplasty performed via an ab-interno approach to preserve the conjunctiva and sclera. Today, canaloplasty is commonly deployed in clinical practice via an ab-interno approach in the treatment of mild and moderate glaucoma. Unlike other minimally invasive glaucoma surgery (MIGS) procedures, which bypass the natural drainage system or remove tissue, ab-interno canaloplasty is a tissue-sparing, implant-free procedure that acts to re-establish the function of the eye’s natural drainage system – achieving an average reduction in IOP of 30%¹ while also preserving the viability of future treatment options. As a result, an increasing number of surgeons are turning to ab-interno canaloplasty to manage their mild-moderate glaucoma patients.



ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

Media enquires:

Kate Hunt
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

Investor enquires:

Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com